| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma |
NCT02746302: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers |
|
|
| Completed | 1 | 62 | RoW | HS-20004, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Healthy | 01/14 | 05/14 | | |
NCT02746315: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers |
|
|
| Completed | 1 | 40 | RoW | HS-20004, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Healthy | 02/15 | | | |
NCT02750007: Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients |
|
|
| Unknown status | 1 | 12 | RoW | HS-20004 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Diabetes Mellitus, Type 2 | 01/17 | | | |
NCT05031871: Pharmacokinetics of HR17031 Injection in Healthy Subjects |
|
|
| Completed | 1 | 24 | RoW | HR17031 injection ；INS068 injection；SHR20004 injection | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 11/21 | 11/21 | | |
NCT06137469: Assessment of Gastric Emptying by SHR20004 in Healthy Subjects |
|
|
| Active, not recruiting | 1 | 28 | RoW | Acetaminophen/SHR20004, Acetaminophen/Placebo | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 02/24 | 02/24 | | |
